GSK stock rises on lung cancer data and JP Morgan view
Published on 09/14/2026 at 12:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
GSK stock (GB0009252882) rose 3.4 percent to 1,830.5p on September 14, 2026 after two lung cancer readouts pushed the British drugmaker higher. Investing.com said the move followed positive clinical data at the 2026 World Conference on Lung Cancer in Seoul.
Two trial readouts
The first dataset covered Jideytro, or zidesamtinib, in the registrational phase I/II ARROS-1 trial. Reuters reported on September 14, 2026 that GSK saw a 94% objective response rate at 15.2 months follow-up, with 90% of patients progression-free at 12 months.
The same Reuters report said 70% of patients with measurable brain metastases achieved complete clearance of detectable brain tumours, and that GSK plans a US regulatory submission in 2026 to expand the indication to first-line treatment. The market took the data as a clearer signal on the oncology build-out.
JP Morgan stays negative
JP Morgan kept an Underweight rating on GSK on September 14, 2026 and left the price target at 1,700p, according to finanzen.ch. The same page showed the stock at 1,830p at the time of the note, which left the shares above the target.
Investing.com also reported that Ris-Rez cut the risk of death by 54 percent versus topotecan in relapsed small cell lung cancer, adding a second catalyst to the same session. The number matters for investors because it adds another data point to the same oncology franchise.
Stock above target
GSK closed at 1,770.50p on September 13, 2026 and traded at 1,830.5p in the latest session cited by Investing.com. That puts the move at 60.0p, or 3.4 percent, above the prior close.
GSK stock facts
- Company: GSK plc
- ISIN: GB0009252882
- Ticker: GSK
- Trading venue: London Stock Exchange
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: FTSE 100
- Price (as of September 14, 2026): 1,830.5p GBP
